{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-032109","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2021-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.943080+00:00","generated_at":"2026-06-27T23:31:59.561523+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lineage Cell Therapeutics launches new $64.1M at-the-market equity offering","bullets":["Prior $25M ATM program terminated; $14.1M remained unsold.","New ATM allows sale of up to $64,133,000 of common shares via Cantor Fitzgerald.","Shares registered under May 2020 and March 2021 shelf registration statements.","Legal opinion of Cooley LLP filed as Exhibit 5.1; proceeds not specified."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-032109","json":"https://secwatch.observer/filing/0001493152-21-032109.json","markdown":"https://secwatch.observer/filing/0001493152-21-032109.md","text":"https://secwatch.observer/filing/0001493152-21-032109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000149315221032109/0001493152-21-032109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000149315221032109/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T23:31:59.561523+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}